Allergan and Merz settle more Alzheimer's drug pay-for-delay allegations for $54M
Allergan and Merz Pharma yesterday unveiled a $54.4 million settlement with a New York labor union for police officers to dismiss their suit (without any admission of guilt) related to the companies’ clamping down on about a dozen generic competitors for the Alzheimer’s drug Namenda.
First approved in 2003, Forest Laboratories (acquired by Actavis in 2014, which then became Allergan) halted Namenda generic competitors until mid-2015, even as FDA began fully approving the generics in 2010. The dozen generic delays were due to so-called pay-for-delay deals, the union alleged in a complaint filed in 2015 in the Southern District of New York.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.